Posted by Michael Wonder on 12 Jan 2021
Janssen's ulcerative colitis treatment to receive reimbursement
12 January 2021 - Janssen Pharmaceutical said Tuesday that the Ministry of Health and Welfare would begin to reimburse Stelara, its active ulcerative colitis treatment, from this month.
Patients eligible for reimbursement include those who have failed or were intolerant to or have medical contra-indications to one or more anti-TNFα or integrin inhibitor treatments.
The ministry based its approval on a Phase 3 UNIFI global clinical trial and two maintenance trials designed to evaluate the drug's efficacy and safety on moderate to severe active patients with ulcerative colitis.
